Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1846 results
September 2018
-
Press release
Alcon confirme son engagement envers la Suisse en perspective de la scission proposée avec Novartis
Le siège social mondial sera basé à Genève à côté du bureau régional d'Alcon pour l'Europe, le Moyen-Orient et l'Afrique La société Alcon cotée en bourse sera enregistrée à Fribourg, où Alcon… -
Story People and Culture
Nudging bias out of the organization
Our Global Head of Talent Acquisition & Staffing talks about ongoing recruitment efforts to create a more diverse and inclusive organization.
-
Ad hoc release
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
August 2018
-
Story Patient Perspectives
The ABCDEs of melanoma prevention and detection
Melanoma survivor T.J. Sharpe discusses skin cancer prevention and detection, and shares tips on how to keep you and your loved ones safe in the sun.
-
Press release
European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma… -
Ad hoc release
Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma
Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising… -
Story Discovery
Teaming up with academia to discover medicines
The Novartis Faculty of Scholars initiative connects academic researchers with deep knowledge and big ideas to scientists in its drug discovery labs.
-
Press release
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in… -
Press release
Novartis erhält die Zulassung für seine CAR-T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission
Die Zulassung durch die EK basiert auf den ersten globalen CAR-T-Zulassungsstudien, an denen Patienten aus acht europäischen Ländern teilnahmen und die ein dauerhaftes Ansprechen und ein… -
Press release
Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode
TRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients[1… -
Ad hoc release
SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation
SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase… -
Story From Our Labs
Neuroscientists target Alzheimer’s “silent stage”
Research exploring the first visible changes in the brain is helping scientists evaluate new potential treatments for Alzheimer’s.